Tuesday, 07 Apr 2020

You are here

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia.  While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events.  A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.

Xie et al, performed a cohort analysis using  Medicare and MarketScan claims data on RA patients who initiated biologic therapies between 2006 and 2-15, looking for specific CV outcomes including myocardial infarction, stroke, and fatal CVD, 

From 88,463 RA patients they calculated the risk of CV events (crude incidence rate (IR) per 1000 patient‐years to range from 11.8 for etanercept to 17.3 for rituximab users. The crude incidence rate for pooled TNFi users was 15.0 (13.9‐16.3).

When compared to tocilizumab, the adjusted hazard ratios for CV events with biologics were:

  • Abatacept 1.01 (0. 79‐1.28)
  • Rituximab 1.16 (0.89‐1.53)
  • Etanercept 1.10 (0.80‐1.51)
  • Adalimumab 1.33 (0.99‐1.80)
  • Infliximab 1.61 (1.22‐2.12) for infliximab.

The data were similar using Marketscan data showing were no statistically significant differences in CVD risk between tocilizumab and any other biologics

Tocilizumab was associated with CVD risk comparable to etanercept, as well as a number of other RA biologics.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

ACR Infusion Guidance During COVID-19 Crisis

The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.

Infusions in the Time of Coronavirus

As they say, necessity is the mother of invention. After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week. One of the few good things to come out of this crisis is that we may learn that in-person visits are not as critical as we thought, which may in turn help our specialty’s access issues.

Earlier Anakinra Initiation Warranted in Still's Disease

An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK). 

A total of 141 AOSD patients were retrospectively studied.

Overall, they found no differences in efficacy if ANK was started within 6 (or 12 mos) vs. thereafter.  

Switching Biologics in JIA

While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era. A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.